In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.
The results of susceptibility testing of 48 phenotyped strains of glycopeptide antibiotic-resistant enterococci are reported. Minimum inhibitory and bactericidal concentrations (MICs and MBCs) were determined for 27 vanA, 17 vanB, and 4 vanC strains. Antibiotics exhibiting the greatest activity included novobiocin (MIC90 = 8 micrograms/ml and MBC90 = 32 micrograms/ml), ramoplanin (MIC90 = 2 micrograms/ml and MBC90 = 4 micrograms/ml), and the streptogramin RP59500 (MIC90 = 4 micrograms/ml and MBC90 = 32 micrograms/ml). These antibiotics warrant further investigation as potentially useful agents, either alone or in combination, for treating enterococcal infections.
Freeman
C
C
Department of Pharmacy, Hartford Hospital, Connecticut, USA.
Robinson
A
A
Cooper
B
B
Mazens-Sullivan
M
M
Quintiliani
R
R
Nightingale
C
C
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D047630:Depsipeptides; D004352:Drug Resistance, Microbial; D016983:Enterococcus / Q000187:drug effects*; D024841:Fluoroquinolones; D005672:Fusidic Acid / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000494:pharmacology; D009287:Naphthyridines / Q000494:pharmacology; D009675:Novobiocin / Q000494:pharmacology; D010456:Peptides, Cyclic; D015363:Quinolones / Q000494:pharmacology; D017334:Teicoplanin / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology; D014769:Virginiamycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D047630:Depsipeptides; D024841:Fluoroquinolones; D009287:Naphthyridines; D010456:Peptides, Cyclic; D015363:Quinolones; C041438:ramoplanin; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D009675:Novobiocin; D005672:Fusidic Acid; D002939:Ciprofloxacin; D017334:Teicoplanin; D014640:Vancomycin; C080163:trovafloxacin; D008911:Minocycline; C061363:sparfloxacin